OncoVista Innovative Therapies (OncoVista Innovative Therapies) ROCE % : 0.00% (As of Sep. 2015)

View and export this data going back to 2005. Start your Free Trial

What is OncoVista Innovative Therapies ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. OncoVista Innovative Therapies's annualized ROCE % for the quarter that ended in Sep. 2015 was 0.00%.

OncoVista Innovative Therapies ROCE % Historical Data

The historical data trend for OncoVista Innovative Therapies's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

OncoVista Innovative Therapies ROCE % Chart

OncoVista Innovative Therapies Annual Data

Trend

Dec05

Dec06

Dec07

Dec08

Dec09

Dec10

Dec11

Dec12

Dec13

Dec14

ROCE %

Get a 7-Day Free Trial

-287.99

OncoVista Innovative Therapies Quarterly Data
	Dec10	Mar11	Jun11	Sep11	Dec11	Mar12	Jun12	Sep12	Dec12	Mar13	Jun13	Sep13	Dec13	Mar14	Jun14	Sep14	Dec14	Mar15	Jun15	Sep15
ROCE %	Get a 7-Day Free Trial															-	-	-	-	-

OncoVista Innovative Therapies ROCE % Calculation

OncoVista Innovative Therapies's annualized ROCE % for the fiscal year that ended in Dec. 2014 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2014 )		(A: Dec. 2013 )		(A: Dec. 2014 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2014 )		(A: Dec. 2013 )		(A: Dec. 2014 )
	=	-2.546	/	( ( (0.096 - 3.216)	+	(0.013 - 4.976) )	/ 2 )
	=	-2.546	/	( (-3.12	+	-4.963)	/ 2 )
	=	-2.546	/	-4.0415
	=	63.00 %

OncoVista Innovative Therapies's ROCE % of for the quarter that ended in Sep. 2015 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Sep. 2015 )		(Q: Jun. 2015 )		(Q: Sep. 2015 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Sep. 2015 )		(Q: Jun. 2015 )		(Q: Sep. 2015 )
	=	-1.268	/	( ( (0.028 - 6.365)	+	(0.061 - 5.951) )	/ 2 )
	=	-1.268	/	( ( -6.337	+	-5.89 )	/ 2 )
	=	-1.268	/	-6.1135
	=	0 %

(1) Note: The EBIT data used here is four times the quarterly (Sep. 2015) EBIT data.

OncoVista Innovative Therapies (OTCPK:OVIT) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

OncoVista Innovative Therapies ROCE % Related Terms

Thank you for viewing the detailed overview of OncoVista Innovative Therapies's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

OncoVista Innovative Therapies (OncoVista Innovative Therapies) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » OncoVista Innovative Therapies Inc (OTCPK:OVIT) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

14785 Omicron Drive, Suite 104, San Antonio, TX, USA, 78245

Website

http://www.oncovista.com

OncoVista Innovative Therapies Inc is a biopharmaceutical company. It is engaged in developing anticancer therapies by utilizing tumor-associated biomarkers.

Executives

Alexander Ruckdaeschel	director	123 EAST 83RD STREET, APT 3-B, NEW YORK NY 10028
Paul A Mieyal	director	C/O WEXFORD CAPITAL LP, 411 WEST PUTNAM AVE, SUITE 125, GREENWICH CT 06830
Charles E Davidson	10 percent owner	C/O WEXFORD CAPITAL LP, 777 SOUTH FLAGLER DRIVE, SUITE 602, WEST PALM BEACH FL 33401
Wexford Capital Lp	10 percent owner	777 WEST PUTNAM AVENUE, 1ST FLOOR, GREENWICH CT 06830
Joseph Jacobs	10 percent owner	C/O WEXFORD CAPITAL LP, 777 SOUTH FLAGLER DRIVE, SUITE 602 EAST, WEST PALM BEACH FL 33401
Wexford Spectrum Trading Ltd	10 percent owner	411 WEST PUTNAM AVENUE, SUITE 125, GREENWICH CT 06830

OncoVista Innovative Therapies (OncoVista Innovative Therapies) Headlines

No Headlines